Castle Biosciences, a Texan cancer diagnostics startup, just closed out the first tranche of a $20 million Series F round.
It’s raised $11.7 million, according to a regulatory filing, and will use the dollars to expand its sales efforts — speeding up clinical adoption of the company’s melanoma tests. Its genetic tests are meant to help doctors figure out the best treatment approach for diseases like uveal melanoma, cutaneous melanoma, esophageal cancer, mesothelioma and glioblastomas. It’s also got a test for rectal cancer in development.
Investors include Industry Ventures, HealthQuest Capital and Mountain Group Partners. Castle Biosciences plans to round out the investment round by the end of the third quarter.
